HEIDELBERG: Brian tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for the patient. Scientists from the German Cancer Research Center (DKFZ) have now been able to show in a study using non-invasive high-resolution 7-Tesla MRI scans that the protein content of tumours correlates with response to treatment and survival.
Glioma is the most common type of brain tumor in adults. This non-neuronal type of tumor arises from glial cells the cells that support and nourish neurons. The term glioma comprises a whole number of brain tumors that vary widely in grade. Some are benign and can be removed completely by surgery. In others, chemotherapy and/or radiotherapy is necessary for addition to surgical removal.
In about half of all glioma patients, an extremely malignant form of the tumor is diagnosed. “Malignant gliomas respond very diversely to treatment, says Daniel Paech from the German Cancer Research Center (DKFZ). In some of the cases, postoperative radiotherapy and chemotherapy are more effective than in others. And whether the tumour has in fact responded to treatment cannot be told before the first follow-up care exam six weeks after treatment ends.” In order to choose the best possible treatment strategy for the patient right from start